Hi Krista,

Great question.

In response to #1- I would say the approval has increased our volume more in terms of new patients coming for second opinions and I’m not quite sure why. I don’t know if it is because the community is uncomfortable recommending this or patients aren’t wanting to get treatment so they come hoping we won’t recommend anything. I would say I’ve noticed a small increase in the volume of returns as we put more patients on adjuvant nivolumab.

In response to #2- We are currently not recommending adjuvant BRAF/MEK.
Thanks,
Lisa